- Home
- CADL
CADL
Candel Therapeutics Inc.
as 11-15-2024 4:00pm EST
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 296.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $14.30 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Candel Therapeutics Inc. (CADL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aguilar-Cordova Estuardo | CADL | 10% Owner | Oct 1 '24 | Sell | $6.93 | 35,002 | $242,641.51 | 988,661 |
Latest Candel Therapeutics Inc. News
CADL Breaking Stock News: Dive into CADL Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
10 days ago
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
GlobeNewswire
12 days ago
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
TipRanks
19 days ago
Candel Therapeutics Advances in Cancer Treatment Trials
GlobeNewswire
20 days ago
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
GlobeNewswire
a month ago
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Simply Wall St.
2 months ago
Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%
GlobeNewswire
2 months ago
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
Compare CADL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CADL Candel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.